On May 13, 2020,Catalent announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19. Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of Ennaidﾒs ENU200 program, a patent-pending, repurposed oral antiviral drug.

Catalentﾒs development site at San Diego will manufacture roller-compacted formulations of ENU200 within capsules for further investigation.